Gilead­'s land­mark CAR-T ap­proval leaves Bris­tol My­ers Squibb scram­bling for sec­ond place

You’ve got to be quick­er than that, Bris­tol My­ers Squibb. Gilead’s Kite scored a land­mark ap­proval for Yescar­ta in large B-cell lym­phoma (LB­CL) on Fri­day, mak­ing it the first CAR-T avail­able in the sec­ond-line lym­phoma set­ting.

The news comes just a few months ahead of an ex­pect­ed de­ci­sion for BMS’ CAR-T ri­val Breyanzi in the same in­di­ca­tion. Gilead says the ap­proval should rough­ly dou­ble Yescar­ta’s mar­ket size in the US — a mile­stone Kite CEO Christi Shaw said has been “years in the mak­ing.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER